Author:
Karabıçak Mustafa,Türk Hakan,Ün Sıtkı,Arslan Erkan,Oğütlü Ahmet
Publisher
Ege Tip Bilimleri Dergisi
Reference21 articles.
1. 1- Özkeçeli R, Satar N, Anafarta K: Üriner sistem taş hastalığı. Bölüm 15, Temel Üroloji Kitabı. 1998;1559- 604.
2. 2- Roehrborn CG ve McConnell JD: “Etiology, pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia”. In Campbell’s Urology, 2002;1297-330.
3. 3- De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012; 61:560-70.
4. 4- Giuliano F. Lower urinary tract symptoms and sexual dysfunction: a common approach. BJU Int 2008;97(Suppl 3):22–6.
5. 5- Lee E, Lee C.Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 1997;80:606–11.